cidara is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. our first product candidate is cd101 iv, a potential once-weekly intravenous therapy being developed for the treatment and prevention of systemic fungal infections. our second product candidate, cd101 topical, is a topical formulation of cd101, the first topical application of the enchinocandin class of anti-fungals, for the treatment of vulvovaginal candidiasis, or vvc. in addition, we have developed a proprietary immunotherapy technology platform, cloudbreak™, which we use to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. we are developing our first cloudbreak development candidate, c001, for the treatment of invasive aspergillosis.
Company profile
Ticker
CDTX
Exchange
Website
CEO
Jeffrey Stein
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
K2 THERAPEUTICS, INC.
SEC CIK
Corporate docs
Subsidiaries
Cidara Therapeutics UK Limited • Cidara Therapeutics (Ireland) Limited ...
CDTX stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
24 Apr 24
8-K
Entry into a Material Definitive Agreement
24 Apr 24
S-8
Registration of securities for employees
22 Apr 24
8-K
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
22 Apr 24
10-K
2023 FY
Annual report
22 Apr 24
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
16 Apr 24
8-K
Submission of Matters to a Vote of Security Holders
5 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
DEF 14A
Definitive proxy
4 Mar 24
PRE 14A
Preliminary proxy
23 Feb 24
Transcripts
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 48.67 mm | 48.67 mm | 48.67 mm | 48.67 mm | 48.67 mm | 48.67 mm |
Cash burn (monthly) | 586.67 k | 367.33 k | 2.85 mm | 2.62 mm | 544.67 k | 2.56 mm |
Cash used (since last report) | 4.01 mm | 2.51 mm | 19.51 mm | 17.92 mm | 3.73 mm | 17.51 mm |
Cash remaining | 44.66 mm | 46.16 mm | 29.16 mm | 30.75 mm | 44.94 mm | 31.16 mm |
Runway (months of cash) | 76.1 | 125.7 | 10.2 | 11.7 | 82.5 | 12.2 |
Institutional ownership, Q2 2023
40.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 57 |
Opened positions | 6 |
Closed positions | 9 |
Increased positions | 18 |
Reduced positions | 11 |
13F shares | Current |
---|---|
Total value | 27.93 bn |
Total shares | 37.28 mm |
Total puts | 2.50 k |
Total calls | 15.00 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
Biotechnology Value Fund L P | 6.86 mm | $8.10 mm |
BVF | 6.86 mm | $7.75 bn |
Nantahala Capital Management | 3.96 mm | $4.48 bn |
Vanguard | 3.21 mm | $3.62 bn |
5am Ventures Iii | 2.01 mm | $4.01 mm |
Alethea Capital Management | 1.63 mm | $1.84 bn |
Renaissance Technologies | 1.55 mm | $1.75 mm |
Point72 Asset Management | 1.25 mm | $1.41 bn |
Omega Fund V | 1.25 mm | $1.59 mm |
5AM Venture Management | 1.13 mm | $1.28 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 24 | Preetam Shah | Common Stock | Grant | Acquire A | No | No | 0 | 108,750 | 0.00 | 335,960 |
15 Mar 24 | Preetam Shah | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.6849 | 217,500 | 148.97 k | 217,500 |
15 Mar 24 | Leslie Tari | Common Stock | Grant | Acquire A | No | No | 0 | 111,250 | 0.00 | 369,931 |
15 Mar 24 | Leslie Tari | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.6849 | 222,500 | 152.39 k | 222,500 |
15 Mar 24 | Sandison Taylor | Common Stock | Grant | Acquire A | No | No | 0 | 128,750 | 0.00 | 475,845 |
15 Mar 24 | Sandison Taylor | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.6849 | 235,500 | 161.29 k | 235,500 |
15 Mar 24 | Stein Jeffrey | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.6849 | 1,040,000 | 712.30 k | 1,040,000 |
15 Mar 24 | Ward Shane | Common Stock | Grant | Acquire A | No | No | 0 | 120,000 | 0.00 | 318,770 |
15 Mar 24 | Ward Shane | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.6849 | 250,000 | 171.23 k | 250,000 |
News
Cidara Therapeutics Reacquires Global Development And Commercial Rights To CD388 From Johnson & Johnson For A One Time Payment Of $85M; Announces Private Placement Financing Of $240M
24 Apr 24
Cidara Therapeutics Announces Divestiture Of Rezafungin To Mundipharma To Focus On Advancing The Clinical Development Of Cloudbreak DFC Pipeline; Transaction Provides Company With An Estimated ~$128M In Cost Savings
24 Apr 24
Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
23 Apr 24
Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
23 Apr 24
Cidara Therapeutics Q4 EPS $(0.04) Beats $(0.10) Estimate, Sales $17.58M Beat $11.54M Estimate
22 Apr 24
Press releases
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline
24 Apr 24
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
22 Apr 24
Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice
22 Apr 24
Cidara Therapeutics Announces Reverse Stock Split
22 Apr 24
Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024
5 Apr 24